These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27663480)

  • 1. The root causes of pharmacodynamic assay failure.
    Ferry-Galow KV; Makhlouf HR; Wilsker DF; Lawrence SM; Pfister TD; Marrero AM; Bigelow KM; Yutzy WH; Ji JJ; Butcher DO; Gouker BA; Kummar S; Chen AP; Kinders RJ; Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):484-91. PubMed ID: 27663480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theory and practice of clinical pharmacodynamics in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):427-35. PubMed ID: 27663474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
    Kinders R; Ferry-Galow K; Wang L; Srivastava AK; Ji JJ; Parchment RE
    Clin Cancer Res; 2014 May; 20(10):2578-86. PubMed ID: 24831280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
    Danson S; Ranson M; Denneny O; Cummings J; Ward TH
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
    Kinders RJ; Hollingshead M; Khin S; Rubinstein L; Tomaszewski JE; Doroshow JH; Parchment RE;
    Clin Cancer Res; 2008 Nov; 14(21):6877-85. PubMed ID: 18980982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay.
    Ferry-Galow KV; Ji J; Kinders RJ; Zhang Y; Czambel RK; Schmitz JC; Herzog J; Evrard YA; Parchment RE
    Semin Oncol; 2016 Aug; 43(4):492-500. PubMed ID: 27663481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.
    Marrero A; Lawrence S; Wilsker D; Voth AR; Kinders RJ
    Semin Oncol; 2016 Aug; 43(4):453-63. PubMed ID: 27663477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.
    Kummar S; Do K; Coyne GO; Chen A; Ji J; Rubinstein L; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):446-52. PubMed ID: 27663476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical validity of a microRNA-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides.
    Benjamin H; Schnitzer-Perlman T; Shtabsky A; VandenBussche CJ; Ali SZ; Kolar Z; Pagni F; ; Bar D; Meiri E
    Cancer Cytopathol; 2016 Oct; 124(10):711-721. PubMed ID: 27223344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers: Implications for cytopathology and specimen collection.
    VanderLaan PA
    Cancer Cytopathol; 2015 Aug; 123(8):454-60. PubMed ID: 25964216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and quality development of biomaterials in the pretest studies of the German National Cohort.
    Kühn A; Nieters A; Köttgen A; Goek ON; Michels K; Nöthlings U; Jacobs G; Meisinger C; Pessler F; Akmatov MF; Kühnisch J; Moebus S; Glocker E; Naus S; Keimling M; Leitzmann M; Linseisen J; Sarioglu H; von Toerne C; Hauck SM; Wallaschofski H; Wichmann HE; Illig T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Nov; 57(11):1255-63. PubMed ID: 25293886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammographically directed breast biopsies: a College of American Pathologists Q-Probes study of clinical physician expectations and of specimen handling and reporting characteristics in 434 institutions.
    Nakhleh RE; Jones B; Zarbo RJ
    Arch Pathol Lab Med; 1997 Jan; 121(1):11-8. PubMed ID: 9111087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability.
    Grenier FC; Ali S; Syed H; Workman R; Martens F; Liao M; Wang Y; Wong PY
    Clin Biochem; 2010 Apr; 43(6):615-20. PubMed ID: 20026020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.
    Sweis RF; Drazer MW; Ratain MJ
    J Clin Oncol; 2016 Feb; 34(4):369-74. PubMed ID: 26668350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Standards, Options and Recommendations: good practice for the management and shipment of histological and cytopathological cancer specimens].
    Denoux Y; Blanc-Vincent MP; Simony-Lafontaine Jl; Verriele-Beurrier V; Briffod M; Voigt JJ
    Bull Cancer; 2002 Apr; 89(4):401-9. PubMed ID: 12016040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
    de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
    Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
    Dowlati A; Haaga J; Remick SC; Spiro TP; Gerson SL; Liu L; Berger SJ; Berger NA; Willson JK
    Clin Cancer Res; 2001 Oct; 7(10):2971-6. PubMed ID: 11595684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer predictive factor testing: the challenges and importance of standardizing tissue handling.
    Hicks DG; Kushner L; McCarthy K
    J Natl Cancer Inst Monogr; 2011; 2011(42):43-5. PubMed ID: 21672896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated UK Recommendations for HER2 assessment in breast cancer.
    Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
    J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.